Zydus Lifesciences Limited, an India-based life-sciences company, announced on Thursday that it has completed an Asset Purchase Agreement, Share Purchase Agreement, and exclusive Licensing Agreement with Agenus Inc (NASDAQ:AGEN), a US-based developer of immuno-oncology therapeutics.

This comprehensive closure follows the receipt of all necessary regulatory approvals, including formal clearance from the Committee on Foreign Investment in the United States (CFIUS).

The transaction establishes Zydus' advanced manufacturing facilities in the global biologics contract development and manufacturing organisation (CDMO) business. All acquired manufacturing assets and operations will be housed under a newly formed, dedicated US-based subsidiary named Zylidac Bio LLC.

Zydus completed its equity investment in Agenus Inc through its venture capital arm, Zynext Ventures.